HK1169832A1 - Novel solid materials of [2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)- 8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza- cyclopentadec-2-yl]-acetic acid and methods for obtaining them [(2s5r8s11s)-5--11-(3--)-8--7--36912 15--1471013---2-]- - Google Patents

Novel solid materials of [2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)- 8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza- cyclopentadec-2-yl]-acetic acid and methods for obtaining them [(2s5r8s11s)-5--11-(3--)-8--7--36912 15--1471013---2-]-

Info

Publication number
HK1169832A1
HK1169832A1 HK12110571.2A HK12110571A HK1169832A1 HK 1169832 A1 HK1169832 A1 HK 1169832A1 HK 12110571 A HK12110571 A HK 12110571A HK 1169832 A1 HK1169832 A1 HK 1169832A1
Authority
HK
Hong Kong
Prior art keywords
2s5r8s11s
cyclopentadec
pentaoxo
pentaaza
guanidino
Prior art date
Application number
HK12110571.2A
Other languages
English (en)
Chinese (zh)
Inventor
Alfred Jonczyk
Clemens Kuehn
Kerstin Seemann
Christoph Saal
Gerald Scholz
Soenke Petersen
Harald Untenecker
Michael Lange
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1169832A1 publication Critical patent/HK1169832A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Peptides Or Proteins (AREA)
HK12110571.2A 2009-05-20 2012-10-24 Novel solid materials of [2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)- 8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza- cyclopentadec-2-yl]-acetic acid and methods for obtaining them [(2s5r8s11s)-5--11-(3--)-8--7--36912 15--1471013---2-]- HK1169832A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09006790 2009-05-20
PCT/EP2010/003100 WO2010133367A2 (en) 2009-05-20 2010-05-20 Novel solid materials of {[2s, 5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them

Publications (1)

Publication Number Publication Date
HK1169832A1 true HK1169832A1 (en) 2013-02-08

Family

ID=41338466

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12110571.2A HK1169832A1 (en) 2009-05-20 2012-10-24 Novel solid materials of [2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)- 8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza- cyclopentadec-2-yl]-acetic acid and methods for obtaining them [(2s5r8s11s)-5--11-(3--)-8--7--36912 15--1471013---2-]-

Country Status (14)

Country Link
US (2) US8586545B2 (es)
EP (2) EP3085704A1 (es)
JP (1) JP5878864B2 (es)
KR (1) KR20120060947A (es)
CN (1) CN102428098B (es)
AU (1) AU2010251385B2 (es)
BR (1) BRPI1012789A2 (es)
CA (1) CA2762652C (es)
EA (1) EA022831B1 (es)
ES (1) ES2578026T3 (es)
HK (1) HK1169832A1 (es)
MX (1) MX2011012231A (es)
WO (1) WO2010133367A2 (es)
ZA (1) ZA201109327B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110086757A (ko) * 2008-11-20 2011-07-29 메르크 파텐트 게엠베하 암을 치료하기 위해 인테그린 리간드를 사용하는 신규한 치료요법 및 약제
PE20121359A1 (es) * 2009-12-10 2012-10-15 Merck Patent Gmbh Composicion farmaceutica que comprende oligopeptidos
ES2720477T3 (es) 2011-06-09 2019-07-22 Merck Patent Gmbh Tratamiento de cánceres y metástasis con suspensiones de Cilengitide en portador

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
PE20121359A1 (es) 2009-12-10 2012-10-15 Merck Patent Gmbh Composicion farmaceutica que comprende oligopeptidos

Also Published As

Publication number Publication date
EP2432801A2 (en) 2012-03-28
ES2578026T3 (es) 2016-07-20
AU2010251385A1 (en) 2012-01-19
BRPI1012789A2 (pt) 2018-01-16
JP5878864B2 (ja) 2016-03-08
US8765684B2 (en) 2014-07-01
EA201101638A1 (ru) 2012-06-29
US20120065142A1 (en) 2012-03-15
CN102428098A (zh) 2012-04-25
AU2010251385B2 (en) 2016-04-14
EP2432801B1 (en) 2016-03-23
CA2762652C (en) 2018-10-02
AU2010251385A8 (en) 2012-02-16
EP3085704A1 (en) 2016-10-26
WO2010133367A3 (en) 2011-10-27
KR20120060947A (ko) 2012-06-12
EA022831B1 (ru) 2016-03-31
MX2011012231A (es) 2011-12-08
ZA201109327B (en) 2012-08-29
WO2010133367A2 (en) 2010-11-25
US20140088022A1 (en) 2014-03-27
US8586545B2 (en) 2013-11-19
JP2012527417A (ja) 2012-11-08
CN102428098B (zh) 2014-11-05
CA2762652A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
HK1181799A1 (en) Microporous material
ZA201202504B (en) Process for the preparation of calcobutrol
EP2497623A4 (en) Jig for manufacture of composite material structure
IL216935A0 (en) Process for the preparation of nacre mechano-structured by mechanosynthesis, mechano-structured nacre thus obtained and uses thereof
ZA201205103B (en) Pharmaceutical composition comprising oligopeptides,preferably cilengitide
PL2151428T3 (pl) Nowy sposób syntezy agomelatyny
GB2466792B (en) Improved composite materials
PL390042A1 (pl) Sposób wytwarzania kwasu chlebowego
EP2404780A4 (en) Structural material
IL219156A0 (en) Process for the preparation of f-series prostaglandins
IL225922A (en) Processes for Preparation of 3 - ((Pyrol-2-Yl) Methylene) -2-Pyrolons by Using 2-Silyloxy-Pyrolines
EP2344468A4 (en) PROCESS FOR PREPARING RAMELTÉON
PL2151429T3 (pl) Nowy sposób syntezy agomelatyny
HK1169832A1 (en) Novel solid materials of [2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)- 8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza- cyclopentadec-2-yl]-acetic acid and methods for obtaining them [(2s5r8s11s)-5--11-(3--)-8--7--36912 15--1471013---2-]-
EG26332A (en) Process for the preparation of benzonoprons
IL212850A0 (en) Novel method for the preparation of granulates of active constituents, and granulates as obtained
TWI367205B (en) Preparation of paricalcitol
IL215022A0 (en) Novel process for the preparation of enaminocarbonyl compounds
IL217460A0 (en) Novel process for the preparation of 4-aminobut-2-enolides
SI2387557T1 (sl) Postopek za pripravo N-(5-(3-dimetilamino-akriloil)-2-fluorofenil)-N-metil-acetamida
IL211382A0 (en) Process for the preparation of ethanedinitrile
IL220160A (en) A process for the preparation of defrasirox
AU2010902509A0 (en) Membrane Material
AU2010901022A0 (en) Membrane Material
PL119266U1 (pl) Stanowisko do badania jakości surowca roślinnego

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210524